The Role of Patents in Drug Development – Telix in Australian Biotechnology Journal
News,
As printed in Australasian Biotechnology Journal September 2022 | Volume 32 | Number…
Read moreNews & Views
First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent
Telix today announces the first commercial dose in New Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11…
Read more
First Patient in Australia Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent
Telix today announces the first commercial dose in Australia of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11…
Read more
First Patient Enrolled in ProstACT TARGET Study
Telix and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s…
Read more
Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data
Telix today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ ¹³¹I] iodo-phenylalanine, or ¹³¹I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent…
Read more
Telix at AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer
We are pleased to announce that Telix is supporting AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from September 22-24…
Read more
Telix Japan – Telix Luncheon Seminar at WFNMB 2022
We are pleased to announce that Telix will be hosting a Luncheon Seminar at the 13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB), to be held at the Kyoto International Conference Center…
Read more
Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment
Telix and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC)…
Read more
Telix Half-Year Results 2022 and Shareholder Update
Telix is pleased to present the Company’s financial results for the half-year ending 30 June 2022, together with a shareholder…
Read more